KRAS and cancer: While the low-risk group showed a positive correlation with Wnt/β-catenin [94] and KRAS signaling [95], both are drivers or participants in various cancers, and their crosstalk between the DNA damage response has been validated, which may provide combination strategies for the treatment of cancer to overcome the dysregulation and deficits in DNA repair [96, 97].